MAFA
BIO icon

MJT & Associates Financial Advisory’s Bio-Rad Laboratories Class A BIO Stock Holding History

MJT & Associates Financial Advisory’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.76K Buy
+6
New +$1.7K ﹤0.01% 394

Other funds holding BIO

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
SGH
Sivik Global Healthcare Greenwich, Connecticut $132M AUM 24.1% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
FISPB
Fideuram - Intesa Sanpaolo Private Banking Turin $3.33B AUM
AB
Amalgamated Bank New York $14.5B AUM 44.3% 1-Year Est. Return
SC
Skylands Capital Milwaukee, Wisconsin $814M AUM 32.37% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

MJT & Associates Financial Advisory's BIO Position: Q2 2026 in Review

MJT & Associates Financial Advisory opened a new position in Bio-Rad Laboratories Class A (BIO) in Q2 2026: 6 shares worth $1.76K. The stake represents ﹤0.01% of the portfolio and ranks #394 among its holdings.

72 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

  • MJT & Associates Financial Advisory held 6 shares of Bio-Rad Laboratories Class A worth $1.76K as of Q2 2026.
  • Bio-Rad Laboratories Class A was a new MJT & Associates Financial Advisory position in Q2 2026.
  • Bio-Rad Laboratories Class A made up ﹤0.01% of MJT & Associates Financial Advisory's portfolio in Q2 2026, its #394 holding.
  • 72 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on MJT & Associates Financial Advisory's 13F filing for Q2 2026, filed 6 Jul 2026.